OncoMatch/Clinical Trials/NCT06962267
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Is NCT06962267 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including TQB2916 and Chemotherapy for pancreatic cancer.
Treatment: TQB2916 · Chemotherapy — This trial was a single-arm, open-label design to evaluate the efficacy and safety of "TQB2916+ gemcitabine + albumin-paclitaxel" as the first-line treatment for metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
The main organs function well
Kidney function
The main organs function well
Liver function
The main organs function well
The main organs function well
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06962267 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages